Global Bipolar Disorder Therapeutic Market 2019-2023

双極性障害治療の世界市場2019-2023

◆タイトル:Global Bipolar Disorder Therapeutic Market 2019-2023
◆商品コード:IRTNTR30013
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年10月31日
◆ページ数:104
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

双極性障害は、気分、エネルギー、および活動レベルの極端な変化を引き起こす躁うつ病としても知られています。気分変動の上昇は、躁病または軽躁病と呼ばれ、精神病の重症度および有無に基づいて異なります。双極性障害は、双極性I、双極性II、および循環性貧血に分類される長期持続性の疾患です。この疾患は、定期的な治療で管理できます。不眠、体重増加・減少、行動変化、および精神不安定は、双極性障害で見られる症状の一部です。双極性障害治療の世界市場は、2019~2023年の間に、年平均成長率2.38%で成長すると予測されています。

主な分析対象企業は、Allergan、AstraZeneca、Eli Lilly、GlaxoSmithKline、Johnson & Johnsonなどです。

当調査レポートでは、双極性障害治療の世界市場について調査・分析し、市場概要、市場環境、双極性障害治療市場規模、製品別(抗精神病薬、抗けいれん薬、従来の精神安定薬、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。

・エグゼクティブサマリー
・調査範囲・調査手法
・双極性障害治療の世界市場概要
・双極性障害治療の世界市場環境
・双極性障害治療の世界市場動向
・双極性障害治療の世界市場規模
・双極性障害治療の世界市場:業界構造分析
・双極性障害治療の世界市場:製品別(抗精神病薬、抗けいれん薬、従来の精神安定薬、その他)
・双極性障害治療の世界市場:地域別市場規模・分析
・双極性障害治療の北米市場規模・予測
・双極性障害治療のヨーロッパ・中東・アフリカ市場規模・予測
・双極性障害治療のアジア太平洋市場規模・予測
・双極性障害治療の主要国分析
・双極性障害治療の世界市場:意思決定フレームワーク
・双極性障害治療の世界市場:成長要因、課題
・双極性障害治療の世界市場:競争環境
・双極性障害治療の世界市場:関連企業情報(ベンダー分析)

About Bipolar Disorder
Bipolar disorder is also known as manic depression that causes extreme shifts in mood, energy, and activity levels. Elevated mood swings are called mania or hypomania, which differs based on the severity and presence of psychosis. Bipolar disorder is a long-lasting condition that can be categorized into bipolar I, bipolar II, and cyclothymia. This condition can be managed with a regular treatment. Insomnia, weight gain or loss, behavioral changes, and psychological imbalances are some of the symptoms witnessed in individuals with bipolar disorder.
Technavio’s analysts forecast the Global Bipolar Disorder Therapeutics Market to grow at a CAGR of 2.38% during the period 2019-2023.

[Covered in this report]
The report covers the present scenario and the growth prospects of the bipolar disorder therapeutics market. To calculate the market size, the report considers the revenue generated from the application of bipolar disorder therapeutics across the globe.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, bipolar disorder therapeutics market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Allergan
• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson
Market driver
• Growing prevalence of mental health disorders (MHDs) across the globe.
• For a full, detailed list, view our report

Market challenge
• Lack of adequate diagnosis process
• For a full, detailed list, view our report

Market trend
• Growing number of strategic alliances
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2023 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Antipsychotics – Market size and forecast 2018-2023
• Anticonvulsants – Market size and forecast 2018-2023
• Traditional mood stabilizers – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALLERGAN
• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO
LOE
Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global cns therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Market size and forecast 2018-2023 ($ mn)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Product – Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Antipsychotics – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antipsychotics – Year-over-year growth 2019-2023 (%)
Exhibit 21: Anticonvulsants – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Anticonvulsants – Year-over-year growth 2019-2023 (%)
Exhibit 23: Traditional mood stabilizers – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Traditional mood stabilizers – Year-over-year growth 2019-2023 (%)
Exhibit 25: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others – Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 33: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 35: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: ALLERGAN – Vendor overview
Exhibit 46: ALLERGAN – Business segments
Exhibit 47: ALLERGAN – Organizational developments
Exhibit 48: ALLERGAN – Geographic focus
Exhibit 49: ALLERGAN – Segment focus
Exhibit 50: ALLERGAN – Key offerings
Exhibit 51: AstraZeneca – Vendor overview
Exhibit 52: AstraZeneca – Business segments
Exhibit 53: AstraZeneca – Organizational developments
Exhibit 54: AstraZeneca – Geographic focus
Exhibit 55: AstraZeneca – Segment focus
Exhibit 56: AstraZeneca – Key offerings
Exhibit 57: Eli Lilly – Vendor overview
Exhibit 58: Eli Lilly – Business segments
Exhibit 59: Eli Lilly – Organizational developments
Exhibit 60: Eli Lilly – Geographic focus
Exhibit 61: Eli Lilly – Segment focus
Exhibit 62: Eli Lilly – Key offerings
Exhibit 63: GlaxoSmithKline – Vendor overview
Exhibit 64: GlaxoSmithKline – Business segments
Exhibit 65: GlaxoSmithKline – Organizational developments
Exhibit 66: GlaxoSmithKline – Geographic focus
Exhibit 67: GlaxoSmithKline – Segment focus
Exhibit 68: GlaxoSmithKline – Key offerings
Exhibit 69: Johnson & Johnson – Vendor overview
Exhibit 70: Johnson & Johnson – Business segments
Exhibit 71: Johnson & Johnson – Organizational developments
Exhibit 72: Johnson & Johnson – Geographic focus
Exhibit 73: Johnson & Johnson – Segment focus
Exhibit 74: Johnson & Johnson – Key offerings
Exhibit 75: Validation techniques employed for market sizing



【掲載企業】

Allergan、AstraZeneca、Eli Lilly、GlaxoSmithKline、Johnson & Johnson

★調査レポート[双極性障害治療の世界市場2019-2023] (Global Bipolar Disorder Therapeutic Market 2019-2023 / IRTNTR30013)販売に関する免責事項
[双極性障害治療の世界市場2019-2023] (Global Bipolar Disorder Therapeutic Market 2019-2023 / IRTNTR30013)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆